Zymework spurns All Blue Capital's $773m takeover bid

Zymeworks' board of directors has rejected an unsolicited, non-binding acquisition offer from an affiliate of UK-based All Blue Capital.

20 May 2022•5 mins read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles